Research
Hormonal
Early Time-Restricted Eating (eTRE) offers specific cardiometabolic benefits (glucose tolerance, insulin sensitivity) independent of weight loss, though practical adherence is low.
If you want metabolic health benefits, try finishing your last meal by 3 PM. However, be aware this is socially difficult and may not be sustainable long-term. If you can't do it, standard timing with good food quality is better than quitting.
ModerateQualifiesMEDIUM confidence
The most consistent clinical benefits of eTRE compared to dTRE or conventional feeding windows (≥12 h) are improved glucose tolerance and insulin sensitivity, which have been repeatedly demonstrated (largely in sedentary subjects with excess body weight)
Why this rating
Based on short-term studies and crossover trials; long-term persistence questionable.
Source
Does Timing Matter? A Narrative Review of Intermittent Fasting Variants and Their Effects on Bodyweight and Body Composition
Alan A. Aragon et al. · Nutrients · 2022
DOI 10.3390/nu14235022
narrative_reviewCited 16×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intermittent fasting variants (ADF, TWF, TRE) produce weight and fat loss effects equivalent to daily caloric restriction (DCR) when total energy intake is matched, with no inherent metabolic advantage to fasting timing.Good
- Intermittent fasting variants (specifically ADF and TWF) cause significant lean mass loss when combined with energy restriction, unless resistance training and high protein intake are utilized.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →